Skip to Content

Measuring cancer care

The Cancer Program at Community Hospital of the Monterey Peninsula has impressive diagnostic and treatment results when compared to regional, state, and national averages, as measured by the American College of Surgeons Commission on Cancer for 2014. The American College of Surgeons Commission on Cancer evaluates Community Hospital’s Cancer Program every three years. 

Radiation therapy for breast cancer 

Radiation therapy after partial mastectomy or lumpectomy dramatically decreases the risk of recurrence.

Performance rate Number of cases
Community Hospital of the Monterey Peninsula 93.5 % 46
California — all cancer programs 88.8 % 4,705
Pacific region* — all cancer programs 90.6 % 7,758
All accredited Comprehensive Cancer Centers in U.S. 92.5 % 39,541
All Commission on Cancer-approved programs in U.S. 92.2 % 64,750

Hormone therapy for breast cancer

For a specific type of breast cancer, hormone therapy after surgery, such as use of the drug Tamoxifen, clearly decreases the risk of recurrence.

Performance rate Number of cases
Community Hospital of the Monterey Peninsula 94.8 % 54
California — all cancer programs 85.7 % 6,643
Pacific region* — all cancer programs 88.2 % 10,825
All accredited Comprehensive Cancer Centers in U.S. 91.3 % 53,907
All Commission on Cancer-approved programs in U.S. 91.1 % 86,823

Lymph-node removal to determine stage of colon cancer

Removal and evaluation of at least 12 lymph nodes next to a patient’s colon cancer enables the doctor to adequately determine whether the cancer has spread to the lymph nodes.  If so, additional treatment will decrease chances of recurrence. 

Performance rate Number of cases
Community Hospital of the Monterey Peninsula 100 % 16
California — all cancer programs 89.1 % 2,567
Pacific region* — all cancer programs 89.1 % 4,082
All accredited Comprehensive Cancer Centers in U.S. 87.9 % 23,703
All Commission on Cancer-approved programs in U.S. 88.1 % 38,071

*Alaska, California, Hawaii, Oregon, and Washington

Read more about the Commission on Cancer’s performance measures.